3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
133
Recurrence
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasms, Plasma Cell
15
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia
7
Immunoglobulin Light-chain Amyloidosis
7
Lymphoma, Non-Hodgkin
6
Amyloidosis
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Burkitt Lymphoma
5
Paraproteinemias
4
Lymphoma, Mantle-Cell
4
Leukemia, Myeloid, Acute
4
Hematologic Diseases
4
Blood Protein Disorders
4
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Lymphoma, B-Cell
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Corneal Diseases
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
Dexamethasone
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled